In instances of repeated corneal transplantation, ulcers and persistent epithelial defects are relatively commonplace, according to a study published in the August 2008 issue of Graefe's Archive for Clinical and Experimental Ophthalmology.
In instances of repeated corneal transplantation, ulcers and persistent epithelial defects are relatively commonplace, according to a study published in the August 2008 issue of Graefe’s Archive for Clinical and Experimental Ophthalmology.
Shimon Rumelt, MD of the department of ophthalmology, Western Galilee-Nahariya Medical Center, Israel and colleagues conducted a retrospective review of patients (n=80) undergoing multiple corneal transplants and regrafts (n=122) between 1985 and 1998, to evaluate complications at a minimum of six, and an average of 31.5, months after the final surgery.
Of the regrafts, 18 were affected by persistent epithelial defects; five had ulcers; and eight had a combination of both persistent epithelial defects and ulcers. Persistent epithelial defects were more likely following cyclocryotherapy for refractory glaucoma. Nine of the 31 regrafts suffering these complications were also positive for bacterial cultures. The graft survival rate was lower in subjects with repeated epithelial defects complicated by ulcers than in any other group, which all had similar levels of graft survival. Of all patients, 10 suffered at least one eyelid abnormality and ocular surface disorder; this was more likely in patients with epithelial defects and/or ulcers than in patients who did not suffer these complications.
Although these complications are common occurrences followed repeated keratoplasties and are associated with low graft survival rates, predisposing factors can be treated.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.